Read the supplement and earn CME credit for your knowledge of the following:
- The pathophysiology of dyspareunia due to vulvovaginal atrophy (VVA) of menopause.
- The underrecognition and undertreatment of dyspareunia due to VVA.
- Efficacy results of randomized placebo controlled trials of ospemifene.
- Adverse events associated with ospemifene.
- Safety data of ospemifine as well as other oral selective estrogen receptor modulators and estrogens.